Medicare ACO Rules For Adopting New Drugs Could Follow D Model – PhRMA
Medicare accountable care organizations should be required to update their clinical guidelines to incorporate new treatments shortly after they are launched, the Pharmaceutical Research and Manufacturers of America suggests in June 6 comments to the Centers for Medicare and Medicaid Services.
You may also be interested in...
In a draft version of its annual instructions to Part D plans, CMS says it is seeking feedback from Part D sponsors and other stakeholders on “possible strategies for achieving better coordination” between stand-alone Medicare Part D plans and accountable care organizations to improve pharmacy care.
Final rule on Medicare accountable care organizations created under the Affordable Care Act is released Oct. 20.
CMS should look for ways to ensure that financial incentives for Medicare accountable care organizations do not promote inappropriate shifts in prescribing from the Part B benefit to Part D, biotech and clinician groups urge in comments filed with the agency June 6.